Although, not all recently identified gain-of-function PPARγ mutants have extensively been characterized and even affect different domains in the protein, at least some of the mutants have implications for “classical” transactivation of PPARγ target genes in bladder cancer. The gene discussed is PPARG; the disease is urinary bladder cancer.